The effect of saffron supplement on patients with Ulcerative colitis

The effect of saffron supplement on Antioxidative Status and Activity illness in patients with Ulcerative colitis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090822002365N21

Enrollment

Registered

2018-04-09

Start date

2018-04-09

Completion date

Unknown

Last updated

2018-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis. Ulcerative colitis

Interventions

Intervention 1: Intervention group: Daily intake of one saffron tablet (100 mg) for 8 weeks (2 months). Intervention 2: Control group: Daily intake of one placebo tablet (containing Maltodextrin) for

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: The willingness to voluntarily participate in the study The diagnosis of ulcerative colitis in the mild to moderate phase by the physician The consumer of only one of the drug groups 5 -Amino salicylic acid (Pentasa, Mesalazine or Asacol), as well as azathioprine BMI greater than 18.5 and less than 30

Exclusion criteria

Exclusion criteria: Changing the type and dosage of the drug over the past month The incidence of other autoimmune diseases, cancer The use of multi vitamin-mineral supplements, antioxidants, and also the use of anticoagulants, blood cholesterol lowering drugs, anti-TNF drugs, and glucocorticosteroids over the past month Pregnancy or lactation in women Non-compliance with treatment (less than 80%)

Design outcomes

Primary

Measure	Time frame
Total Antioxidant Capacity (TAC). Timepoint: Before the intervention and two months later of intervention. Method of measurement: Concentration of TAC in serum using ELISA kit.;Superoxide dismutase (SOD). Timepoint: Before the intervention and two months later of intervention. Method of measurement: Concentration of SOD in serum using ELISA kit.;Malondialdehyde (MDA). Timepoint: Before the intervention and two months later of intervention. Method of measurement: Concentration of MDA in serum using ELISA kit.;Glutathione (GSH). Timepoint: Before the intervention and two months later of intervention. Method of measurement: Concentration of GSH in serum using ELISA kit.;Activity illness. Timepoint: Before the intervention and two months later of intervention. Method of measurement: Using the SCCAI-Q questionnaire.	—

Measure

Time frame

Total Antioxidant Capacity (TAC). Timepoint: Before the intervention and two months later of intervention. Method of measurement: Concentration of TAC in serum using ELISA kit.;Superoxide dismutase (SOD). Timepoint: Before the intervention and two months later of intervention. Method of measurement: Concentration of SOD in serum using ELISA kit.;Malondialdehyde (MDA). Timepoint: Before the intervention and two months later of intervention. Method of measurement: Concentration of MDA in serum using ELISA kit.;Glutathione (GSH). Timepoint: Before the intervention and two months later of intervention. Method of measurement: Concentration of GSH in serum using ELISA kit.;Activity illness. Timepoint: Before the intervention and two months later of intervention. Method of measurement: Using the SCCAI-Q questionnaire.

—

Secondary

Measure	Time frame
Body Mass Index. Timepoint: Before the intervention and two months later of intervention. Method of measurement: Using the ratio of weight (kilogram) to the square of height (meter).;Weight. Timepoint: Before the intervention and two months later of intervention. Method of measurement: Using the digital scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammadreza Vafa

Iran University of Medical Sciences

vafa.m@iums.ac.ir+98 21 8670 4743

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026